ALK and inflammatory myofibroblastic tumor: Multiple preclinical studies have shown that specific small-molecule ALK TKIs can delay tumor growth and/or induce tumor regression in xenograft and transgenic models.[10] However, few reports are available on the efficacy of ensartinib treatment for metastasis IMT, with no consistent prediction of the efficacy of TKI in metastatic IMT.